Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 7, 2011, Pages 2146-2153

  Rapa, Ida ^a   Saggiorato, Enrico ^a   Giachino, Daniela ^a   Palestini, Nicola ^a   Orlandi, Fabio ^a   Papotti, Mauro ^a   Volante, Marco ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; S6 KINASE;

ARTICLE; BRAF GENE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE; GENE ACTIVATION; H GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; K RAS GENE; N GENE; PHOSPHATIDYLINOSITOL 3 KINASE GENE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RET GENE; THYROID MEDULLARY CARCINOMA; WESTERN BLOTTING;

ADULT; CARCINOMA, MEDULLARY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; RAS PROTEINS; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 79960094269     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2010-2655     Document Type: Article

References (26)

1. Hoff AO, Hoff PM 2007 Medullary thyroid carcinoma. Hematol Oncol Clin North Am 21:475-488; viii
2. Ye L, Santarpia L, Cote GJ, El-Naggar AK, Gagel RF 2008 High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma. J Clin Endocrinol Metab 93:4367-4372 (Pubitemid 352789533)
3. Hickey JG, Myers SM, Tian X, Zhu SJ, V Shaw JL, Andrew SD, Richardson DS, Brettschneider J, Mulligan LM 2009 RET-mediated gene expression pattern is affected by isoform but not oncogenic mutation. Genes Chromosomes Cancer 48:429-440
4. Ameur N, Lacroix L, Roucan S, Roux V, Broutin S, Talbot M, Dupuy C, Caillou B, Schlumberger M, Bidart JM 2009 Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways. Endocr Relat Cancer 16:1261-1272
5. Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, Trink B, Ladenson PW, Sidransky D, Xing M 2005 Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 90:4688-4693 (Pubitemid 41159359)
6. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404 (Pubitemid 37452745)
7. Perren A, Schmid S, Locher T, Saremaslani P, Bonvin C, Heitz PU, Komminoth P 2004 BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. Endocr Relat Cancer 11:855-860 (Pubitemid 40065557)
8. Goutas N, Vlachodimitropoulos D, Bouka M, Lazaris AC, Nasioulas G, Gazouli M 2008 BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Res 28:305-308 (Pubitemid 351362917)
9. Gallel P, Pallares J, Dolcet X, Llobet D, Eritja N, Santacana M, Yeramian A, Palomar-Asenjo V, Lagarda H, Mauricio D, Encinas M, Matias-Guiu X 2008 Nuclear factor-κB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma. Hum Pathol 39:994-1001
10. Ning L, Kunnimalaiyaan M, Chen H 2008 Regulation of cell-cell contact molecules and the metastatic phenotype of medullary thyroid carcinoma by the Raf-1/MEK/ERK pathway. Surgery 144: 920-924; discussion 924-925
11. Plaza-Menacho I, van der Sluis T, Hollema H, Gimm O, Buys CH, Magee AI, Isacke CM, Hofstra RM, Eggen BJ 2007 Ras/ERK1/2- mediated STAT3 Ser727 phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity, and transformation. J Biol Chem 282:6415-6424 (Pubitemid 47100884)
12. Faggiano A, Talbot M, Lacroix L, Bidart JM, Baudin E, Schlumberger M, Caillou B 2002 Differential expression of galectin- 3 in medullary thyroid carcinoma and C-cell hyperplasia. Clin Endocrinol (Oxf) 57:813-819 (Pubitemid 36963009)
13. Liu L, Sakai T, Sano N, Fukui K 2004 Nucling mediates apoptosis by inhibiting expression of galectin-3 through interference with nuclear factor κB signalling. Biochem J 380:31-41 (Pubitemid 38725726)
14. Segouffin-Cariou C, Billaud M 2000 Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/ AKT signaling pathway. J Biol Chem 275:3568-3576 (Pubitemid 30083066)
15. Pitt SC, Chen H 2008 The phosphatidylinositol 3-kinase/akt signaling pathway in medullary thyroid cancer. Surgery 144:721-724
16. Kunnimalaiyaan M, Ndiaye M, Chen H 2006 Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery 140:1009-1014; discussion 1014-1015
17. Grozinsky-Glasberg S, Rubinfeld H, Nordenberg Y, Gorshtein A, Praiss M, Kendler E, Feinmesser R, Grossman AB, Shimon I 2010 The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells. Mol Cell Endocrinol 315:87-94
18. Volante M, Rapa I, Gandhi M, Bussolati G, Giachino D, Papotti M, Nikiforov YE 2009 RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab 94:4735-4741
19. Ceccherini I, Pasini B, Pacini F, Gullo M, Bongarzone I, Romei C, Santamaria G, Matera I, Mondellini P, Scopsi L, Pinchera A, Pierotti MA, Romeo G 1997 Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET protooncogene. Oncogene 14:2609-2612 (Pubitemid 27273522)
20. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460 (Pubitemid 23179393)
21. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Höppener JW, van Amstel HK, Romeo G, Lips CJ, Buys CH 1994 A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367:375-376
22. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A 2008 Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow- up study. J Clin Endocrinol Metab 93:682-687 (Pubitemid 351398539)
23. Wells Jr SA, Santoro M 2009 Targeting the RET pathway in thyroid cancer. Clin Cancer Res 15:7119-7123
24. Santarpia L, Ye L, Gagel RF 2009 Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma. J Intern Med 266:99-113
25. Zatelli MC, Minoia M, Martini C, Tagliati F, Ambrosio MR, Schiavon M, Buratto M, Calabrese F, Gentilin E, Cavallesco G, Berdondini L, Rea F, degli Uberti EC 2010 Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr Relat Cancer 17:719-729
26. de Groot JW, Plukker JT, Wolffenbuttel BH, Wiggers T, Sluiter WJ, Links TP 2006 Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol (Oxf) 65:729-736 (Pubitemid 44772352)